These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections. Braden RL; Anadkat MJ Support Care Cancer; 2016 Sep; 24(9):3943-50. PubMed ID: 27117557 [TBL] [Abstract][Full Text] [Related]
3. Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches. Nikolaou V; Stratigos A; Antoniou C; Kiagia M; Nikolaou C; Katsambas A; Syrigos K Dermatology; 2010; 220(3):243-8. PubMed ID: 20110632 [TBL] [Abstract][Full Text] [Related]
4. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab. Bragg J; Pomeranz MK Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934 [TBL] [Abstract][Full Text] [Related]
6. A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. Pongpudpunth M; Demierre MF; Goldberg LJ J Cutan Pathol; 2009 Dec; 36(12):1303-7. PubMed ID: 19519875 [TBL] [Abstract][Full Text] [Related]
7. Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash. Tohyama M; Hamada M; Harada D; Kozuki T; Nogami N; Monden N; Kajiwara T; Nishina T J Dermatol; 2020 Feb; 47(2):121-127. PubMed ID: 31803963 [TBL] [Abstract][Full Text] [Related]
8. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor. Shin JU; Park JH; Cho BC; Lee JH Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507 [TBL] [Abstract][Full Text] [Related]
9. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. Amitay-Laish I; David M; Stemmer SM Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888 [TBL] [Abstract][Full Text] [Related]
11. The management of EGFR inhibitor adverse events: a case series and treatment paradigm. Wnorowski AM; de Souza A; Chachoua A; Cohen DE Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636 [TBL] [Abstract][Full Text] [Related]
12. Erosive pustular dermatosis of the scalp-like eruption due to gefitinib: case report and review of the literature of alopecia associated with EGFR inhibitors. Toda N; Fujimoto N; Kato T; Fujii N; Nakanishi G; Nagao T; Tanaka T Dermatology; 2012; 225(1):18-21. PubMed ID: 22922680 [TBL] [Abstract][Full Text] [Related]
14. Erlotinib-induced purpuric papulopustular eruption treated with pulsed azithromycin. Akoglu G; Yavuz SO; Metin A Indian J Pharmacol; 2016; 48(3):324-6. PubMed ID: 27298507 [TBL] [Abstract][Full Text] [Related]
15. Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature. Nazzaro G; Giacalone S; Bortoluzzi P; Veraldi S; Marzano AV Dermatol Online J; 2021 Feb; 27(2):. PubMed ID: 33818981 [TBL] [Abstract][Full Text] [Related]
16. Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients. Bellini V; Bianchi L; Pelliccia S; Lisi P J Cutan Pathol; 2016 Mar; 43(3):211-8. PubMed ID: 26423594 [TBL] [Abstract][Full Text] [Related]
17. Malassezia folliculitis presented as acneiform eruption after cetuximab administration. Cholongitas E; Pipili C; Ioannidou D J Drugs Dermatol; 2009 Mar; 8(3):274-5. PubMed ID: 19271376 [TBL] [Abstract][Full Text] [Related]
18. Sebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruption. Takata T; Tarutani M; Zouboulis CC; Sano S J Dermatol Sci; 2012 May; 66(2):165-8. PubMed ID: 22440861 [No Abstract] [Full Text] [Related]
19. The Most Common Cutaneous Side Effects of Epidermal Growth Factor Receptor Inhibitors and Their Management. Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B Acta Dermatovenerol Croat; 2015; 23(4):282-8. PubMed ID: 26724881 [TBL] [Abstract][Full Text] [Related]